Effect of hematoporphyrin derivative 2 on estrogen receptors in experimental mammary tumors

✍ Scribed by Raymond J. Lanzafame; David W. Rogers; John O. Naim; H. Raul Herrera; J. Raymond Hinshaw

• Publisher: John Wiley and Sons
• Year: 1987
• Tongue: English
• Weight: 244 KB
• Volume: 7
• Category: Article
• ISSN: 0196-8092
• DOI: 10.1002/lsm.1900070314

✦ Synopsis

This study reports the effect of hematoporphyrin derivative 2 (HPD2) on estrogen receptors (ER) in the animal model used to develop the clinical ER assay. Fifty 200-g female Sprague-Dawley rats were given 20 mg of dimethylbenzanthracene by gastric intubation. Spontaneous mammary tumors occurred in 35 animals. Animals were anesthetized and 50% of each tumor was removed when the tumors were 2 cm in diameter. Animals were then randomized to receive 5 mg/kg (group A), 10 mg/kg (group B), or 0 mglkg (group C) HPD2 intravenously 48 hours after biopsy. The remaining tumor was excised 48 hours post HPD2 injection. All samples were weighed, placed on ice, and frozen to -70°C. ER assay was performed by batch run. Results (fmol/mg cytosol) were as follows: All animals (n=35) pre HPD2 34.2 f 5.4, post HPD2 34.2 5.8; group A: ( n = l l ) pre HPD2 33.9 7.9, post HPD2 37.1 _+ 7.8; group B: (n=13) pre HPD2 29.2 f 3.8, post HPD2 25.5 + 3.6; group C: ( n = l l ) pre HPD2 40.3 k 5.2, post HPD2 41.5 f 7.9. HPD2 does not affect ER in this animal model. Confirmatory studies with human tumor material must be completed.